Net sales were 103,207 million yen, up 10.6% year-over-year; operating income was 2,949 million yen, down -14.7%; quarterly net income attributable to owners of parent was 3,630 million yen, down -12.4%. Earnings guidance for the second quarter onward has been revised and the full-year forecast is under review. There is impact related to the full acquisition of Takara Bio.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2531","jir_company_name":"Takara Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2531-20261023-01.pdf","jir_short_summary":"Net sales were 103,207 million yen, up 10.6% year-over-year; operating income was 2,949 million yen, down -14.7%; quarterly net income attributable to owners of parent was 3,630 million yen, down -12.4%. Earnings guidance for the second quarter onward has been revised and the full-year forecast is under review. There is impact related to the full acquisition of Takara Bio.","jir_summary":"### Performance Overview\nFor the cumulative consolidated first quarter, Takara Holdings Inc. reported net sales of 103,207 million yen (up 10.6% year-over-year), while operating income decreased to 2,949 million yen (down -14.7%). Ordinary income was 3,157 million yen (down -9.1%), and quarterly net income attributable to owners of parent was 3,630 million yen (down -12.4%). By segment, contributions came from Takara Shuzo and the Takara Shuzo International Group, while acquisition-related expenses for the Takara Bio Group and structural reform costs were recorded.\n\n### Outlook and Financial Position\nRegarding revisions to the consolidated earnings forecast for the second quarter, please refer to the attached materials; the full-year forecast is currently under review and is scheduled to be announced on November 10, 2026. The most recent financial position shows total assets of 535,691 million yen and an equity ratio of 46.0%; however, additional acquisition of Takara Bio shares has reduced capital surplus and lowered the equity ratio.","jir_financial_highlights":"Net Sales: 103,207 million yen (Year-over-Year +10.6%)\nOperating Income: 2,949 million yen (Year-over-Year -14.7%)\nOrdinary Income: 3,157 million yen (Year-over-Year -9.1%)\nQuarterly Net Income Attributable to Owners of Parent: 3,630 million yen (Year-over-Year -12.4%)\nTotal Assets: 535,691 million yen (Compared with previous fiscal year-end +21,890 million yen)\nEquity Ratio: 46.0% (Declined from 50.5% at previous fiscal year-end)","jir_category":"","jir_hashtags":"#TakaraHoldingsIncIR, #Earnings","jir_key_figures":"Net Sales: 103,207 million yen\nOperating Income: 2,949 million yen\nQuarterly Net Income Attributable to Owners of Parent: 3,630 million yen","jir_meta_title":"Takara Holdings Inc. Q1 FY2027 Earnings Report\uff5cNet Sales 103,207 million yen (+10.6%)","jir_meta_description":"Key points from Takara Holdings Inc.'s Q1 FY2027 earnings report. Net sales rose 10.6% year-over-year, operating income declined -14.7%, and the full-year outlook is under review. Analysis of segment trends and changes in capital structure (Earnings Report).","jir_og_title":"Takara Holdings Inc. Q1 Earnings Report\uff5cNet Sales 103,207 million yen","jir_og_description":"Takara Holdings Inc.'s Q1 results show increased net sales but decreased operating income. The full-year outlook is undecided; this summary explains key points including the impact of the Takara Bio acquisition.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2026 1Q\\\",\\\"FY2027 1Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[93348,103207]}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2026 1Q\\\",\\\"FY2027 1Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[3456,2949]}]}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Net Income Attributable to Owners of Parent Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2026 1Q\\\",\\\"FY2027 1Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income\\\",\\\"data\\\":[4145,3630]}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Takara Shuzo\\\",\\\"Takara Shuzo International Group\\\",\\\"Takara Bio Group\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2027 1Q\\\",\\\"data\\\":[30245,60334,9204,8331]}]}\"}, {\"jir_chart_id\": \"debt_and_equity\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2026-end\\\",\\\"FY2027 1Q-end\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[50.5,46.0]}]}\"}]","ir_related_company":8130,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-133824","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n